Home › Research › Treatments
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease
Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE et al.. Neurology, 2006-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.
What this study adds
Evidence grade: High
This is a trial of 70 participants. The gamma-secretase inhibitor LY450139 lowered Abeta(1-40) in plasma by 38.2%, but the decrease in cerebrospinal fluid was not significant. Reported effect size: decreased by 38.2%; 9.55%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., et al. (2006). Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000198762.41312.e1
Vancouver
Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006. doi:10.1212/01.wnl.0000198762.41312.e1. PMID: 16505324.
BibTeX
@article{siemers2006-16505324,
author = {Siemers, E. R. and Quinn, J. F. and Kaye, J. and Farlow, M. R. and Porsteinsson, A. and Tariot, P. and Zoulnouni, P. and Galvin, J. E. and others},
title = {{Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease}},
journal = {Neurology},
year = {2006},
doi = {10.1212/01.wnl.0000198762.41312.e1},
pmid = {16505324},
url = {https://doi.org/10.1212/01.wnl.0000198762.41312.e1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant).
- Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.
Why it matters
The gamma-secretase inhibitor LY450139 lowered Abeta(1-40) in plasma by 38.2%, but the decrease in cerebrospinal fluid was not significant. The authors suggest higher drug doses may be needed to produce a measurable decrease in CSF Abeta.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants70
- Effect sizedecreased by 38.2%; 9.55%
- Evidence strengthHigh
How this study scored 71/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 1 / 4 | 70 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 295 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.4 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 5 / 6 | Cited 23.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Patrick C. May: h-index 38 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Oregon Health & Science University: institution h-index 1,025 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16505324) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.